IP Library Granted Patent US 8,920,806
Granted Patent B2
US 8,920,806 · App. 10/575,049 · Granted Dec 30, 2014

Method of modulating inflammatory response by downregulation of activin

Inventors: David Morritz De Kretser (Surrey Hills, AU); David James Phillips (Hughesdale, AU); Kristian Lee Jones (Hawthorn East, AU); Robyn O'Hehir (Melbourne, AU); Shane Patella (Oakleigh, AU)
Assignee: Paranta Biosciences Limited
A61K38/1709C07K16/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,920,806
App. No.
10/575,049
Granted
Dec 30, 2014
Kind
B2
Abstract

The present invention relates generally to a method of modulating an inflammatory response in a mammal and to agents useful for same. More particularly, the present invention relates to a method of modulating an inflammatory response in a mammal by modulating the functional activity of activin and thereby modulating the pro-inflammatory mediator cascade. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by an aberrant, unwanted or otherwise inappropriate inflammatory response including, inter alia, sepsis and inflammation of the airway. The present invention is further directed to methods for identifying and/or designing agents capable of modulating activin mediated regulation of the inflammatory response.

Claims (7)

1. A method of treating cystic fibrosis in a mammal in need thereof, said method comprising administering follistatin to said mammal.

2. The method of claim 1 , wherein the follistatin is administered as follistatin 315.

3. The method of claim 1 , wherein the follistatin is administered as follistatin 288.

4. The method of claim 1 , wherein the follistatin is administered by a route selected from the group consisting of injection, oral administration, oral inhalation, or a nebulizer.

5. The method of claim 1 , wherein the mammal is human.

6. The method according to claim 1 , wherein the method treats localized inflammatory responses associated with the cystic fibrosis.

7. The method according to claim 1 , wherein the method treats airway inflammation associated with the cystic fibrosis.

Assignments (4)
CHANGE OF NAME Recorded Dec 12, 2012
From: PARANTA BIOSCIENCES PTY LTD
To: PARANTA BIOSCIENCES LIMITED
Reel/Frame 029457/0814 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2011
From: MONASH UNIVERSITY; WILSON, KATHRYN MOIRA; DE KRETSER, DAVID MORRITZ; PHILLIPS, DAVID JAMES; JONES, KRISTIAN LEE; O'HEHIR, ROBYN; PATELLA, SHANE; SEBIRE, KIMBERLEY LOUISE; SIEVERT, WILLIAM; SMOLICH, JOSEPH; MCGAW, DAVID; FENNESSY, PAUL
To: ITFP PTY LTD
Reel/Frame 026136/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2011
From: ITFP PTY LTD
To: PARANTA BIOSCIENCES PTY LTD
Reel/Frame 026137/0123 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2006
From: DE KRETSER, DAVID MORRITZ; PHILLIPS, DAVID JAMES; JONES, KRISTIAN LEE; O'HEHIR, ROBYN; PATELLA, SHANE; WILSON, KATHRYN MOIRA; SEBIRE, KIMBERLEY LOUISE
To: MONASH UNIVERSITY
Reel/Frame 018726/0398 →
Priority Claims (3)
AU 2003905461 · Oct 6, 2003 · national
AU 2004902056 · Apr 16, 2004 · national
AU 2004904834 · Aug 24, 2004 · national
Continuity (1)
Related Publication 20070248609A1 · Oct 25, 2007